Portage Biotech Files 6-K, Incorporates by Reference

TL;DR

Portage Biotech (PTGE) filed a 6-K on Dec 5, incorporating info into its S-8. Standard update.

AI Summary

Portage Biotech Inc. filed a Form 6-K on December 5, 2024, to report information for the month of December 2024. The filing indicates that this report is incorporated by reference into the company's registration statement on Form S-8 (File No. 333-275842). The company is incorporated in the British Virgin Islands and its fiscal year ends on March 31.

Why It Matters

This filing serves as an update for investors regarding the company's ongoing reporting obligations and its incorporation of information into existing registration statements.

Risk Assessment

Risk Level: low — This filing is a routine report and does not appear to contain significant new financial or operational information that would immediately impact risk.

Key Players & Entities

• Portage Biotech Inc. (company) — Filer of the 6-K report
• 333-275842 (other) — File number for the Form S-8 registration statement
• December 5, 2024 (date) — Filing date of the Form 6-K

FAQ

Filing Documents

• f6k_120524.htm (6-K) — 9KB
• 0001171843-24-006770.txt ( ) — 11KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024 Commission File Number: 001-40086 Portage Biotech Inc. (Translation of registrant's name into English) Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands, VG1110 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F INCORPORATION BY REFERENCE This report on Form 6-K (including any exhibits attached hereto) shall be deemed to be incorporated by reference into the registration statement on Form S-8 (File No. 333-275842) of Portage Biotech Inc. (including any prospectuses forming a part of such registration statement) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Management Changes Pursuant to the terms of that certain Services Agreement, dated as of December 15, 2021, by and between Portage Development Services Inc., a wholly-owned subsidiary of Portage Biotech, Inc (the "Company"), and Ian Walters, M.D. (the "Services Agreement"), Dr. Walters's term as Chief Executive Officer ("CEO") of the Company will expire and he will cease serving as CEO of the Company, effective as of the close of business on December 14, 2024. A copy of the Services Agreement is included as Exhibit 10.5 to the Company's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on August 1, 2022. Board Changes In connection with the foregoing, Dr. Walters is no longer a member of the Company's Board of Directors (the "Board"), effective December 4, 2024. In addition, Justin Stebbing, M.D., Ph.D., a current member of the Board, was appointed Chair of the Board. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: December 5, 2024 PORTAGE BIOTECH INC. By: /s/ Andrea Park Andrea Park Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR